Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.
about
Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screensCRISPulator: a discrete simulation tool for pooled genetic screensSystematic comparison of CRISPR/Cas9 and RNAi screens for essential genes.Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction networkSuppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers.Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.Tuning the proteasome to brighten the end of the journey.Mapping the spatial proteome of metastatic cells in colorectal cancer.Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1.Inhibition of Proteasome Activity Induces Formation of Alternative Proteasome Complexes.CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine.Elucidating drug targets and mechanisms of action by genetic screens in mammalian cells.CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.Proteasome dysregulation in human cancer: implications for clinical therapies.Oncogenic addiction to high 26S proteasome level.
P2860
Q33654299-0AC4DF09-415F-4286-8A78-D93E455A8A1EQ33922903-D51D15B3-B573-43F8-8209-672C4798FE43Q34046778-C72D558B-3494-45D3-9420-C403BF118D7FQ36303485-8367F995-5DE4-4D95-B17A-326836950A53Q37590014-22A57E50-6F56-4315-AEA6-ED177163C3BFQ37684348-A743734B-1F47-454C-8139-9D97EF722519Q38559265-1B24BEA9-34F7-4AC0-AEB0-24483470662FQ38598295-18A6E9E0-3840-48D5-BF35-FD15C08C0FDBQ38706865-8CA76154-DD66-438B-8361-42D4AA5DDCE3Q41362934-811EE177-7C71-4C52-B42B-216C1FD19910Q41740375-11AF6D63-A1FC-4CC5-BE99-85F2AEBE331CQ42431910-C3F76DA2-CA41-4AC3-A14C-86810F4CB153Q46190066-033DB3FC-5FDA-4738-A39B-D3F4CABCE9D8Q46347911-7F59781D-A600-4C49-B6AD-3D5710D9BC3FQ49660927-18FB35E5-05ED-4918-A3A6-7603D39D2DEBQ50077966-FAFBB051-E638-4C93-861C-8B83DA515634Q55559653-ABD2F4FE-F3C0-4C02-B72F-43458CDA5E7F
P2860
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Paradoxical resistance of mult ...... s of 19S proteasomal subunits.
@ast
Paradoxical resistance of mult ...... s of 19S proteasomal subunits.
@en
type
label
Paradoxical resistance of mult ...... s of 19S proteasomal subunits.
@ast
Paradoxical resistance of mult ...... s of 19S proteasomal subunits.
@en
prefLabel
Paradoxical resistance of mult ...... s of 19S proteasomal subunits.
@ast
Paradoxical resistance of mult ...... s of 19S proteasomal subunits.
@en
P2093
P2860
P50
P356
P1433
P1476
Paradoxical resistance of mult ...... s of 19S proteasomal subunits.
@en
P2093
Alana G Lerner
Chunaram Choudhary
Irina Maric
Jamie Hahn
Neha Korde
Olga Simakova
Thomas Wild
Tonia J Buchholz
P2860
P304
P356
10.7554/ELIFE.08153
P407
P577
2015-09-01T00:00:00Z